ProMIS Neurosciences
Yahoo Finance • last month
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to repor... Full story
Yahoo Finance • 2 months ago
ProMIS Neurosciences GAAP EPS of -$0.29
* ProMIS Neurosciences press release [https://seekingalpha.com/pr/20199117-promis-neurosciences-announces-second-quarter-2025-financial-results-and-corporate-highlights] (NASDAQ:PMN [https://seekingalpha.com/symbol/PMN]): Q2 GAAP EPS of... Full story
Yahoo Finance • 3 months ago
ProMIS Neurosciences Announces Private Placement Financing
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting... Full story
Yahoo Finance • 3 months ago
ProMIS Neurosciences raises $3.2M through ATM offering, PIPE financing
* ProMIS Neurosciences (NASDAQ:PMN [https://seekingalpha.com/symbol/PMN]) has raised [https://seekingalpha.com/pr/20172913-promis-neurosciences-announces-0_8-million-registered-direct-offering-priced-at-the-market]$0.8 million at-the-mar... Full story
Yahoo Finance • 3 months ago
ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310
ProMIS Neurosciences Inc. (NASDAQ:PMN) announced Monday it has mutually agreed with BTIG, LLC to terminate its At The Market Offering Agreement, effective immediately. The agreement, originally established on January 5, 2024, allowed the c... Full story
Yahoo Finance • 3 months ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Opendoor Technologies Inc. 343,720,987 3.38 2.615 3.2042 +0.9542 TNF Pha... Full story
Yahoo Finance • 7 months ago
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
CAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic... Full story
Yahoo Finance • 7 months ago
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded pr... Full story
Yahoo Finance • 8 months ago
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded pro... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolde... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
Raised $20.4 million in PIPE gross proceeds to support continued development of Company’s PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases Dosing of first subjects in first-in-human P... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeu... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfold... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
Presented compelling preclinical data supportingtherapeutic potential of PMN310 to treat Alzheimer’s disease,and the promise of disease prevention with acomputationally derived Alzheimer’s disease vaccine candidate atAAIC 2023 TORONTO, On... Full story
Yahoo Finance • 2 years ago
ProMIS Announces Completion of Continuance
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN) (“ProMIS” or the “Corporation”) is pleased to announce that it has completed its continuance (the “Contin... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
Company to voluntarily delist from the Toronto Stock Exchange (TSX)Last trading day on TSX will be July 21, 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasd... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting tox... Full story
Yahoo Finance • 2 years ago
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMNRFXF) (“ProMIS” or the “Corporation”) is issuing this release to correct the URL required to virtually acce... Full story
Yahoo Finance • 2 years ago
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s diseasePresented preclinical data supporting target identification and candidate differentiation across pipeline o... Full story
